Skip to search formSkip to main contentSkip to account menu

ponatinib

Known as: 3-(2-(imidazo(1,2-b)pyridazin-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-y-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide, Benzamide, 3-(2-Imidazo(1,2-B)Pyridazin-3-Ylethynyl)-4-Methyl-N-(4-((4-Methyl-1- Piperazinyl)Methyl)-3-(Trifluoromethyl)Phenyl), Ponatinibum 
An orally bioavailable multitargeted receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. Ponatinib… 
National Institutes of Health

Related topics

Related topics

10 relations

Narrower (2)

AP24534Iclusig

Broader (4)

Antineoplastic AgentsImidazolesProtein Kinase InhibitorsPyridazines
NCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase Inhibitionponatinib 45 MG Oral Tablet [Iclusig]ponatinib hydrochloride

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Novel targeted therapeutics for MEN2.
The rearranged during transfection (RET) proto-oncogene was recognized as the multiple endocrine neoplasia type 2 (MEN2) causing… 
Review
2017
Review
2017
Current approach to the treatment of chronic myeloid leukaemia.
Highly Cited
2017
Highly Cited
2017
First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive…
Background. The incorporation of tyrosine kinase inhibitors (TKIs) in treatment schemes of Ph+ ALL has remarkably improved… 
2017
2017
Frontline hyper-CVAD plus ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Updated results of a phase II study.
7013Background: The combination of chemotherapy plus a TKI is highly effective in Ph+ ALL. In this phase II study, we evaluated… 
2014
2014
Fatal progressive cerebral ischemia in CML under third-line treatment with ponatinib
The third generation tyrosine kinase inhibitor (TKI) ponatinib extends the therapeutic armamentarium for the management of… 
2013
2013
Cardio-Vascular Events Occurring On Ponatinib In Chronic Phase Chronic Myeloid Leukemia Patients, Preliminary Analysis Of a Multicenter Cohort
Ponatinib represents an alternative option for chronic phase (CP) chronic myeloid leukemia (CML) patients (pts) failing 2 or more… 
Review
2013
Review
2013
The N 550 K / H Mutations in FGFR 2 Confer Differential Resistance to PD 173074 , Dovitinib , and Ponatinib ATP-Competitive Inhibitors 1
We sought to identify fibroblast growth factor receptor 2 (FGFR2) kinase domain mutations that confer resistance to the pan-FGFR… 
2012
2012
Molecular characterization of deletions of the long arm of chromosome 5 (del(5q)) in 94 MDS/AML patients
Molecular characterization of deletions of the long arm of chromosome 5 (del(5q)) in 94 MDS/AML patients 
2012
2012
Ponatinib for chronic myeloid leukemia.
The treatment of patients with chronic myeloid leukemia (CML) must be ranked as one of the great medical success stories of the… 
Review
2011
Review
2011
Tyrosine kinase inhibitor therapy for chronic myeloid leukemia: approach to patients with treatment-naive or refractory chronic-phase disease.
The 21st century ushered in the dawn of a new era of targeted therapeutics and a dramatic shift in the management of chronic… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)